Hertility is proud to announce a major milestone in our journey to transform women’s health—we have successfully raised $16.3 million in funding. This significant investment reinforces our commitment to reshaping the future of reproductive healthcare with data-driven insights and personalized care. Hertility, a women’s health company built by women, for women, is at the forefront of pioneering advanced diagnostic testing capabilities. Our innovative approach empowers individuals to better understand their reproductive health, addressing fertility decline and the onset of menopause through cutting-edge at-home testing coupled with specialized gynaecological expertise.
The funds raised will be strategically deployed to accelerate our research trials and enhance our diagnostic portfolio. With nearly one-third of women experiencing a reproductive health issue at some point, our mission to reduce the diagnostic timeline is more critical than ever. By investing in state-of-the-art technology and expanding our specialist care network, we are taking a bold step towards creating tailored health pathways that address everything from ovarian health and fertility options to broader hormonal challenges like PCOS. Moreover, the investment will further our capability to diagnose nine of the most common gynaecological pathologies that may affect fertility or indicate potential risks for gynaecological cancers.
At its core, this funding supports the Reproductive Revolution—a movement dedicated to transforming attitudes around reproductive health and promoting proactive, informed healthcare choices. By providing expert advice, educational resources, and accessible at-home testing, Hertility is committed to dismantling outdated models and empowering women to take control of their health, both in personal spaces and in the workplace. This is a pivotal moment for our company and the future of reproductive healthcare alike.
